Filtered By:
Condition: Thrombosis
Procedure: Coronary Angioplasty

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 869 results found since Jan 2013.

Short- and Long-term cardiovascular outcomes in insulin-treated versus non-insulin-treated diabetes mellitus patients after percutaneous coronary intervention: a systematic review and meta-analysis
CONCLUSION: Despite a tremendous technical success rate of multi-vessel stenting, people living with diabetes who were being treated with insulin had higher long-term, and short-term mortality rates, MI, TLR, TVR, and stroke compared to people living with diabetes who were being treated with means other than insulin and are more prone to detrimental cardiovascular outcomes.PMID:34906538 | DOI:10.1016/j.ihj.2021.12.004
Source: Indian Heart J - December 15, 2021 Category: Cardiology Authors: Wardah Hassan Javeria Saquib Mahima Khatri Syeda Kanza Kazmi Sohny Kotak Hani Hassan Jawad Ahmed Source Type: research

Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial
This study received approval from the Certified Review Board of Osaka University (a certified research ethics committee by the Japanese Clinical Research Act). The findings will be disseminated through peer-reviewed publications and conference presentations. Trial registration number Japan Registry of Clinical Trials: jRCTs051190053; Pre-results.
Source: BMJ Open - December 14, 2021 Category: General Medicine Authors: Sotomi, Y., Kozuma, K., Kashiwabara, K., Higuchi, Y., Ando, K., Morino, Y., Ako, J., Tanabe, K., Muramatsu, T., Nakazawa, G., Hikoso, S., Sakata, Y., on behalf of the OPTIMA-AF Investigators Tags: Open access, Cardiovascular medicine Source Type: research

White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial
Conclusion There was no association between baseline WBCc and 30-day or 5-year clinical outcomes after PCI or CABG. The absence of a clear incremental increase in events with increasing WBCc in the current analysis indicates that WBCc should not routinely be used as a prognostic marker or to guide revascularization decisions in patients with LMCAD.
Source: Coronary Artery Disease - December 9, 2021 Category: Cardiology Tags: PCI Source Type: research

High Human Antimicrobial Peptide LL-37 Level Predicts Lower Major Adverse Cardiovascular Events after an Acute ST-Segment Elevation Myocardial Infarction
CONCLUSIONS: High basal plasma level of human LL-37 may predict lower 3-year risks of ischemic cardiovascular events in patients after STEMI.PMID:34853213 | DOI:10.5551/jat.63221
Source: Journal of Atherosclerosis and Thrombosis - December 2, 2021 Category: Cardiology Authors: Hanjun Zhao Zhaoxue Sheng Yu Tan Runzhen Chen Jinying Zhou Jiannan Li Qianyu Zhao Ying Wang Xiaoxiao Zhao Yi Chen Peng Zhou Chen Liu Li Song Hongbing Yan Source Type: research

Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis
ConclusionStable CAD patients treated with clopidogrel and carriedCYP2C19 LoF alleles undergoing PCI were associated with significantly increased risk of MACE compared to non-carriers, even markedly significant for Asian patients.
Source: Cardiovascular Drugs and Therapy - December 1, 2021 Category: Cardiology Source Type: research

Aspirin in the Modern Era of Cardiovascular Disease Prevention
Methodist Debakey Cardiovasc J. 2021 Sep 24;17(4):36-47. doi: 10.14797/mdcvj.293. eCollection 2021.ABSTRACTAspirin's antithrombotic effects have a long-established place in the prevention of cardiovascular disease (CVD), and its traditional use as a core therapy for secondary prevention of CVD is well recognized. However, with the advent of newer antiplatelet agents and an increasing understanding of aspirin's bleeding risks, its role across the full spectrum of modern CVD prevention has become less certain. As a consequence, recent trials have begun investigating aspirin-free strategies in secondary prevention. For exampl...
Source: Methodist DeBakey Cardiovascular Journal - November 26, 2021 Category: Cardiology Authors: Ella Murphy James M G Curneen John W McEvoy Source Type: research